Mexico will be part of phase 3 of the testing period corresponding to the vaccine developed by the German company CureVac, dedicated to the development of biopharmaceutical products; subsequently the formula will be distributed by the pharmaceutical company Bayer once it is suitable for its use.
Michael Martínez, member of the COVID-19 program of the Health System of the Tecnológico de Monterrey (SSTM), pointed out that stage 3 will start this month, being directed by the Tec Salud. Currently, 2 thousand people are requested to start with the experimental phase of the vaccine, once the goal of volunteers is achieved, the vaccine will be applied to 50% of the sample, while the remaining half will be administered placebos.
Once the development of the vaccine is completed and it proves to be reliable and effective, the dose will be applied free of charge to the test subjects who had previously been injected with the placebo.
In order to be considered as a possible volunteer, it is requested to be older than 18 years old and to reside in the Monterrey metropolitan area, since the authorities will need to check the patient's progress in person and be aware of any anomaly that could occur in the individual because of the vaccine.
The health professional added that this represents a great opportunity for people who will not receive their vaccine until the middle or even the end of the year, as is the case with the young population between 18 and 30 years of age.
Similarly, people who suffer from certain diseases may also qualify as volunteers, as long as their family doctor considers it relevant and their health status is kept under control.
RELATED VIDEO: AMLO reiterates commitment to vaccinate older adults by the end of March